ZHEJIANG JINHUA CONBA BIO-PHARM CO LTD

Overview

ZHEJIANG JINHUA CONBA BIO-PHARM CO LTD is an active pharmaceutical ingredient (API) supplier with 7 active FDA Type II Drug Master Files, covering ACETYLCYSTEINE (USP); ARIPIPRAZOLE USP; AZITHROMYCIN, USP; DABIGATRAN ETEXILATE MESYLATE; OMEPRAZOLE; RIVAROXABAN USP.

API / Drug Master Files

ZHEJIANG JINHUA CONBA BIO-PHARM CO LTD holds 7 active (11 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• AZITHROMYCIN, USPActive2026-03-26
• DABIGATRAN ETEXILATE MESYLATEActive2026-02-11
• ACETYLCYSTEINE (USP)Active2024-08-05
• RIVAROXABAN USPActive2023-11-29
• TAZOBACTAM USPActive2023-09-12
• ARIPIPRAZOLE USPActive2018-07-09
• OMEPRAZOLEActive2010-09-01
• TAMSULOSIN HYDROCHLORIDEInactive2015-12-11
• ESOMEPRAZOLE MAGNESIUM DIHYDRATEInactive2015-11-04
• AMIKACIN SULFATE USPInactive2013-11-27
• ARIPIPRAZOLEInactive2012-04-24

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to ZHEJIANG JINHUA CONBA BIO-PHARM CO LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.